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Abstract
Background: Scopolamine is a well-known cholinergic antagonist that causes amnesia in human and animal models.
Scopolamine-induced amnesia in rodent models has been widely used to understand the molecular, biochemical,
behavioral changes, and to delineate therapeutic targets of memory impairment. Although this has been linked to the
decrease in central cholinergic neuronal activity following the blockade of muscarinic receptors, the underlying molecular
and cellular mechanism(s) particularly the effect on neuroplasticity remains elusive. In the present study, we have
investigated (i) the effects of scopolamine on the molecules involved in neuronal and glial plasticity both in vivo and in vitro
and (ii) their recovery by alcoholic extract of Ashwagandha leaves (i-Extract).
Methodology/Principal Findings: As a drug model, scopolamine hydrobromide was administered intraperitoneally to mice
and its effect on the brain function was determined by molecular analyses. The results showed that the scopolamine caused
downregulation of the expression of BDNF and GFAP in dose and time dependent manner, and these effects were markedly
attenuated in response to i-Extract treatment. Similar to our observations in animal model system, we found that the
scopolamine induced cytotoxicity in IMR32 neuronal and C6 glioma cells. It was associated with downregulation of neuronal
cell markers NF-H, MAP2, PSD-95, GAP-43 and glial cell marker GFAP and with upregulation of DNA damage- cH2AX and
oxidative stress- ROS markers. Furthermore, these molecules showed recovery when cells were treated with i-Extract or its
purified component, withanone.
Conclusion: Our study suggested that besides cholinergic blockade, scopolamine-induced memory loss may be associated
with oxidative stress and Ashwagandha i-Extract, and withanone may serve as potential preventive and therapeutic agents
for neurodegenerative disorders and hence warrant further molecular analyses.
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Introduction
Memory function is vulnerable to a variety of pathological
processes including neurodegenerative diseases, stroke, tumors,
head trauma, hypoxia, cardiac surgery, malnutrition, attention-
deficit disorder, depression, anxiety, side effects of medication, and
aging [1]. Severe memory loss and deficits in broad range of
cognitive abilities are commonly categorized as age-pathology
because of its frequent occurrence in later part of human lifespan.
Memory loss is often the most disabling feature of many disorders,
impairing the normal daily activities of the patients and
profoundly affecting their families. Animal models of memory
impairment have been used to understand its molecular basis and
search its therapeutic targets. Scopolamine- induced amnesia
rodent model is one of the well-established animal models of
memory dysfunction [2]. Scopolamine is a non-selective musca-
rinic receptor antagonist that inhibits central cholinergic neuronal
activity and impairs learning and short-term memory. It influences
the expression of a broad spectrum of genes including those
associated with muscarinic receptor signaling pathways, apoptosis,
cytoskeleton reconstruction, protein trafficking and cell differen-
tiation in rat brain [3]. However, molecular details and the role of
these signaling pathways remain undefined [4].
Memory is tightly associated with brain plasticity related events
at different levels and involves changes in the expression of
molecules, intracellular signaling cascades, synaptic strength and
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including brain derived neurotrophic factor (BDNF), a member of
the neurotrophin family of growth factors that is widely expressed
throughout the mammalian brain along with its high affinity
receptor TrkB [5] and plays a crucial role in development,
maintenance and function of the central nervous system (CNS).
Accumulating data have suggested that the neuronal activity
regulates BDNF transcription, transport to dendrites and secretion
that in turn modulates synaptogenesis, synaptic plasticity and
memory formation [6]. Furthermore, it has been established that
glial cells and their resident protein glial fibrillary acidic protein
(GFAP) integrate neuronal input, modulate synaptic activity and
process signals related to learning and memory by formation of
cytoskeletal filaments [7]. It provides structural support to neurons
and is necessary for CNS morphogenesis [8] and hence is
considered as a marker of glial plasticity controlling the structure,
adhesion and proliferation of astrocytes, neuron-glia interactions
and mechanisms of memory formation. Functional impairment
and modifications of these molecules that signal and articulate
memory function are widely considered in development of
nootropics including drugs, supplements, biomolecules and their
derivatives. One of the widely used herbal extract includes
Ashwagandha (Withania somnifera) that has been shown to enhance
neuritic regeneration and synaptic reconstruction. However, the
molecular mechanism of such activity is not well understood. In
the present study, we have investigated the neuroprotective
potential of the alcoholic extract of Ashwagandha leaves (i-Extract)
that is rich in withaferin A and withanone (i-Factor) in
scopolamine-induced amnesia mouse and brain cell culture
(IMR32, neuronal and C6, glioma) models.
Results
Scopolamine affected the BDNF and GFAP mRNA
expression in mouse cerebrum in a dose and time
dependent manner
In order to determine the effect of scopolamine on neuroplas-
ticity, we analyzed BDNF (transcript variant-1) and GFAP mRNA
in mouse cerebrum. In RT-PCR analysis, 692 nucleotides
fragment of BDNF mRNA and 641 nucleotides fragment of
GFAP mRNA were amplified. We found that both BDNF and
GFAP were downregulated in scopolamine treated mouse
cerebrum. Furthermore, the effect was dose dependent. As
compared to control saline treatment (set at 100%), scopolamine
treated mice showed dose dependent drastic reduction in
expression level of BDNF (1 mg/kg BW-67%, 3 mg/kg BW-
58%, 6 mg/kg BW- 44% and 10 mg/kg BW-12%; P,0.05)
(Figure 1, A and B). Similarly, GFAP message was reduced in a
dose dependent, but moderate manner (1 mg/kg BW-94%, 3 mg/
kg BW-81%, 6 mg/kg BW- 75% and 10 mg/kg BW-8% P,0.05)
(Figure 1A and 1B). The difference in BDNF was found to be
statistically significant between control and treated groups.
Figure 1. Effect of scopolamine on BDNF and GFAP expression in mice brain. Dose and time dependent effects of scopolamine (SC- 1, 3, 6,
10 mg/Kg BW) on the level of expression of BDNF and GFAP mRNA in mouse cerebrum: (A) RT-PCR analysis showing BDNF (692 bp), GFAP mRNA
(641 bp) and internal control GAPDH (108 bp). The band intensity was quantitated densitometrically (represented as relative units) by normalizing
with GAPDH) from three independent experiments (6) SEM. (B) Histogram represents percent relative units of BDNF and GFAP expressions from
three independent experiments (6) SEM. *denotes significant differences (P,0.05) between the groups. (C) Time (1, 3, 6, 24 h) dependent effect of
scopolamine (SC- 3 mg/Kg BW) on expression of BDNF and GFAP mRNA in mouse cerebrum. Data was quantitated (D) as mentioned above.
doi:10.1371/journal.pone.0027265.g001
Ashwagandha Protects Scopolamine-Induced Damage
PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e27265However, for GFAP message, all the groups, except 1 mg/kg BW
group, showed significant alteration. Since BDNF and GFAP have
been shown to be involved in regulation of neuronal plasticity and
differentiation, these data suggested that the scopolamine affected
neuroplasticity.
In order to investigate whether scopolamine mediated effect on
neuroplasticity was long lasting or transient, the expression level of
BDNF and GFAP was examined after 1, 3, 6 and 24 h of
scopolamine treatment; 3 mg/kg BW that resulted in 40%
decrease in BDNF in comparison to only 15–20% for GFAP
and has been considered physiologically relevant in other studies
[9–12] was selected. As seen in Figure 1C and 1D, down-
regulation of BDNF and GFAP occurred in a time-dependent
manner. As compared to the untreated saline control (set at
100%), BDNF expression level gradually decreased until 6 h and
thereafter it showed increase at 24 h (1 h- 63%, 3 h- 50%, 6 h-
46% and 24 h- 67% P,0.05). Statistical analysis revealed that the
change between control and treated groups, except between 3 h
and 6 h, were statistically significant (Figure 1C and 1D).
Similarly, GFAP message level also showed time-dependent
reduction until 6 h and thereafter it increased to control level by
24 h (1 h- 95%, 3 h- 85%, 6 h- 58% and 24 h-100% P,0.05). In
case of GFAP, comparison was statistically significant between
control and treated groups except between the control and 1 h,
and control and 24 h groups (Figure 1C and 1D). The data from
this pilot study implied that the scopolamine-mediated effects on
BDNF and GFAP expression were transient and lasted for nearly
24 h.
Effect of i-Extract on scopolamine-induced
downregulation of BDNF and GFAP in mouse cerebrum
To assess the effects of i-Extract on scopolamine-mediated
decrease in levels of BDNF and GFAP, we analyzed both message
and protein level of BDNF and GFAP in cerebrum samples from
mice that were treated with i-Extract and scopolamine. Expression
analysis of BDNF mRNA (Figure 2A) showed that the scopol-
amine reduced its level to about half; and pretreatment of i-Extract
markedly attenuated the decrease by 50% (Group 3- i-Extract
100 mg/kg BW) and 200% in Group 4 (i-Extract 200 mg/kg BW)
and Group 5 (i-Extract 300 mg/kg BW). In the western blot
analysis, anti-BDNF polyclonal rabbit antiserum detected pro-
BDNF as ,32-kDa and mature BDNF as ,15-kDa (Figure 2B)
and revealed a pattern similar to BDNF mRNA; although the
extent of alteration was milder. Scopolamine reduced both
precursor and mature BDNF protein to about 3/4 level that was
statistically significant and i-Extract attenuated the decrease by
27% for pro-BDNF and 33% for mature BDNF in Group 3 (i-
Extract 100 mg/kg BW), 36% for pro BDNF and 80% for mature
Figure 2. Ashwagandha i-Extract treatment and reversal of scopolamine-induced decrease in BDNF and GFAP expression in mice
brain. Effects of i-Extract (100, 200, 300 mg/Kg BW) on scopolamine (SC- 3 mg/Kg BW) induced decrease in mRNA (A) and protein (B) expression
levels of BDNF and GFAP in mouse cerebrum. Data was quantitated and is shown as percent relative units. *denotes significant differences (P,0.05)
between the SC group and i-Extract group. #denotes significant differences (P,0.05) between the control and SC group.
doi:10.1371/journal.pone.0027265.g002
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BDNF and 95% for mature BDNF in Group 5 (i-Extract 300 mg/
kg BW) P,0.05.
Expression analysis of GFAP message (Figure 2A) showed that
the scopolamine reduced its level to about 3/4th whereas i-Extract
attenuated the decrease by 24% (Group 3, i-Extract 100 mg/kg
BW), 35% (Group 4, i-Extract 200 mg/kg BW) and 58% (Group
5, i-Extract 300 mg/kg BW P,0.05). Effect of i-Extract on GFAP
protein (Figure 2B) followed a similar pattern. In the Western blot
analysis, anti-GFAP polyclonal rabbit antiserum recognized GFAP
of ,45-kDa. Scopolamine reduced GFAP protein level to about
half and i-Extract attenuated the decrease by 54% (Group 3, i-
Extract 100 mg/kg BW), 88% (Group 4, i-Extract 200 mg/kg
BW) and 93% (Group 5, i-Extract 300 mg/kg BW) P,0.05.
Moreover, the effect of pre- and post-treatment with i-Extract
(200 mg/kg BW) on scopolamine (3 mg/kg BW)-induced alter-
ations were also examined. In pre-treatment, mice were first
treated with i-Extract followed by scopolamine, while in post-
treatment mice were treated first with scopolamine followed by i-
Extract. The data revealed that whereas the pretreatment of i-
Extract reverted the scopolamine-induced decrease in BDNF, the
post-treatment was ineffective (Figure 3A and 3B). GFAP message
and protein level (Figure 3A and 3B) were increased by i-Extract
treatments (both pre and post) (Figure 3A and 3B). Furthermore,
we found that the administration of i-Extract, without scopolamine
upregulated the expression of BDNF mRNA as well as the protein
suggesting that the i-Extract has factors that may enhance
neuroplasticity. The data revealed that pre-treatment of i-Extract
was more effective in attenuating scopolamine-induced downreg-
ulation of BDNF message and protein as compared to post-
treatment of i-Extract. Moreover, the administration of i-Extract
alone, without scopolamine, upregulated BDNF message and
protein level. In case of GFAP, both pre- and post- treatment of i-
Extract equally attenuated scopolamine induced downregulation
but to a relatively lower extent as compared to BDNF.
Effect of i-Extract on scopolamine-induced toxicity to
glial and neuronal cells
In order to understand the molecular mechanism of scopol-
amine-induced toxicity and its recovery in response to i-Extract
treatment, and to define the active component for neuroprotec-
tion, we adopted glioma and neuronal cell culture models and
examined their effects on cell survival. As shown in Figure 4A, cells
showed cytotoxic response to scopolamine treatment, and when
cultured in the presence of i-Extract, rich in withaferin A and
withanone (Figure 4B) supplemented medium exhibited recovery
(Figure 4A). As shown in Figure 4C, scopolamine also caused cell
death in neuronal (IMR32) cells. Cytotoxicity as seen by
appearance of apoptotic cells was confirmed by TUNEL assay.
Cells pre-treated and recovered in medium supplemented either
with i-Extract or its component withanone showed recovery from
apoptosis (Figure 4D). Withaferin A did not protect the cells
against scopolamine toxicity (Figure 4C and 4D; and data not
shown).
Figure 3. Effect of pre- and post-treatment with Ashwagandha i-Extract on scopolamine-induced changes in BDNF and GFAP
expression in mice brain. Effects of pre, post and per se treatment of i-Extract (200 mg/Kg BW) on mRNA expression (A) and protein (B) levels of
BDNF and GFAP in the mouse cerebrum. Data was quantitated and is presented as percent relative units. Lane 1-Control, Lane 2-scopolamine, Lane 3-
post-treatment with i-Extract, Lane 4-per se treatment of i-Extract, Lane 5-Pre-treatment with i-Extract. *denotes significant differences (P,0.05)
between the SC group and i-Extract group. #denotes significant differences (P,0.05) between Control and SC group.
doi:10.1371/journal.pone.0027265.g003
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In order to investigate whether the presence of i-Extract and
withanone lead to recovery from scopolamine-induced toxicity
associated with neuro/glial cell differentiation, we examined the
levels of GFAP in i-Extract and scopolamine treated cells
(Figure 5A). As shown, scopolamine treated cells showed decrease
in GFAP expression. Of note, GFAP expression recovered when
cells were pretreated either with i-Extract or withanone.
Furthermore, i-Extract and withanone treated cells showed
astrocytic extensions, characteristic of glial cell differentiation
(Figure 5B). Withaferin A-treated cells did not show such astrocytic
differentiation (Figure 5B).
Neuronal cell protection by i-Extract and withanone
We examined the neuronal cell markers in IMR32 cells treated
with scopolamine, i-Extract and withanone. As shown in Figure 6A
and 6B, neuronal cell markers MAP2 (Microtubule-associated
protein), NF-H (Neurofilament NF-H), PSD-95 (Postsynaptic
marker protein) and GAP-43 (Growth-associated protein 43, an
intrinsic determinant of neuronal development and plasticity)
exhibited downregulation in the scopolamine treated cells,
however the cells pretreated and recovered either in i-Extract or
in withanone-supplemented medium showed recovery of all the
four neuronal cell markers (Figure 6A and 6B). Withaferin A-
treated cells did not show such recovery either in the Western blot
or immunostaining assays (Figure 6A and 6B).
Protection of scopolamine-induced DNA and oxidative
stress by i-Extract and withanone
We hypothesized that scopolamine may cause DNA and
oxidative stress to cells and i-Extract may have protective
function. In order to investigate the hypothesis, we examined
DNA and oxidative damage induced proteins in cells treated with
scopolamine and i-Extract. As shown in Figure 7A and 7B,
scopolamine treated cells showed high levels of gamma cH2AX
and ROS. Cells pre-treated and recovered in i-Extract supple-
mented medium showed decreased levels of these proteins and
similar change was obtained with withanone (Figure 7C and 7D).
On the other hand, withaferin A treated cells showed high levels
of cH2AX, p53, p21 and ROS (Figure 7 and data not shown).
These data suggested that i-Extract and withanone treated cells
were protected against the DNA damage and oxidative stress
caused by scopolamine.
Discussion
Ashwagandha (Withania somnifera: solanaceae) is one of the
widely used herbs in the Indian traditional system of medicine
Figure 4. Effect of i-Extract on scopolamine-induced toxicity in C6 glioma and IMR32 neuroblastoma cells. (A) i-Extract treatment
resulted in increased viability of C6 cells. (B) Composition of i-Extract (the content of Withaferin A and Withanone is shown. (C) IMR32 cells treated
with scopolamine and i-Extract, Withaferin A and Withanone (i-Factor) supplemented medium are shown. (D) TUNEL assay of the control and treated
cells (as indicated) showed apoptosis in scopolamine treated cells. Pre-treatment of cells and recovery in i-Extract supplemented medium showed
downregulation of scopolamine induced apoptosis.
doi:10.1371/journal.pone.0027265.g004
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extracts from different parts of the plant including roots, shoot and
leaves have been claimed to have large variety of health promoting
effects. The biologically active constituents of Ashwagandha leaves
include alkaloids, steroidal lactones and saponins that have been
proposed to possess anti-stress, anti-oxidant, analgesic, immuno-
modulatory, adaptogenic and immunostimulant properties. Some
studies have also reported anticancer, neuroregeneration and
cholinergic activities in Ashwagandha extracts [13–15]. Our
present study showed that the scopolamine down-regulated
neuroplasticity molecules and caused damage to glial and neuronal
cells as assessed by the respective markers in mouse cerebrum and
in C6 and IMR32 cell models. Furthermore, we found that the
damage was dose and time dependent. These findings suggested
cholinergic regulation of the neuroplasticity molecules as well as
provide insight into the molecular basis of scopolamine-induced
memory impairment. i-Extract attenuated scopolamine-induced
down-regulation of neuronal and glial markers as well as recovered
cells from oxidative stress. Such neuroprotective effect of i-Extract
might be attributed to activation of muscarinic receptor mediated
downstream signaling pathway and thereby transcriptionally
regulating the neuroplasticity molecules.
Scopolamine mediated down-regulation of BDNF and
GFAP suggests alteration in their basal transcriptional
machinery by M1 receptor signaling pathway
As demonstrated, scopolamine affected both neuronal and glial
plasticity markers in dose and time dependent manner. It
drastically reduced BDNF message (transcript variant 1) in mouse
cerebrum. BDNF transcript variant 1 is neural tissue specific,
expressed in all the regions of the brain [16] and associated with
cognitive disorders like Alzheimer’s disease [17]. Moreover, it is
also reported that expression of transcripts containing exons I and
III are most sensitive to activity-dependent regulation and are
readily induced in response to synaptic activity [18–20].
Interestingly, the scopolamine-mediated down-regulation of
BDNF message was transient and reverted back by 24 h to the
level, close to that of control. Our results are consistent with earlier
report on the involvement of cholinergic neuronal activity in the
regulation of BDNF and NGF mRNAs in the developing and
adult rat hippocampus [21]. Likewise, Kotani et al [22] observed
that the scopolamine reduces BDNF message while cholinergic
agonists (carbachol and pilocarpine) upregulate the mRNAs of
BDNF and TrkB in the rat hippocampus. Some recent studies
have shown that the cholinergic hypofunction induced by the
Figure 5. Ashwagandha i-Extract and withanone treatment and recovery of glial cell differentiation marker GFAP in scopolamine-
treated C6 cells. Level of GFAP expression in C6 glioma cells treated with either scopolamine or scopolamine and i-Extract/withaferin A/withanone
as described in material and methods. Levels detected by western blotting (A) and immunocytostaining (B) are shown. Quantitation from two
independent experiments was performed using SigmaStat (Aspire Software International). Actin was used as an internal control.
doi:10.1371/journal.pone.0027265.g005
Ashwagandha Protects Scopolamine-Induced Damage
PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27265Figure 6. Recovery of neuronal cell differentiation markers in scopolamine-treated cells in response to Ashwagandha i-Extract and
withanone treatment. Level of MAP2, NF-H, GAP43 and PSD-95 expression in IMR32 neuroblastoma cells treated with either scopolamine or
scopolamine and i-Extract/withaferin A/withanone as described in material and methods. Levels of expression as detected by western blotting (A)
and immunocytostaining (B) are shown. Quantitation was performed as described for Figure 5.
doi:10.1371/journal.pone.0027265.g006
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192IgG-saporin impaired the memory acquisition, possibly
through hippocampal Arc and BDNF down-regulation via
muscarinic receptors [23]. Furthermore, in case of neurodegen-
erative disorders like Alzheimer’s disease, Garzon et al [17] have
observed 3–4 fold reductions in BDNF mRNA and protein levels
in the hippocampus and cerebral cortex of human brain.
It is likely that the down-regulation of BDNF message by
muscarinic antagonist scopolamine might be associated with M1
receptor mediated signaling pathway. Muscarinic acetylcholine
receptors (mAChRs) belong to the G-protein-coupled receptor
superfamily that transduces signals through PKC, Ca
2+, cAMP
and MAP kinase pathway [24–26], and thus modulate neuronal
functions including long-term potentiation and synaptic plasticity
implicated in learning and memory [27].
It has been established that the BDNF expression is controlled
by the Ca
2+ regulated transcription factor CREB that remains
bound to BDNF promoter in an inactive form. Phosphorylation of
CREB by calcium-regulated kinase cascades stimulates the
recruitment of components of the basal transcription machinery
to the BDNF promoter, and then new BDNF mRNA is
synthesized [28]. On the other hand, drastic reduction in BDNF
level by scopolamine could also be linked to scopolamine-mediated
down-regulation of presenilins [3] that directly or indirectly
through amyloid b influences transcriptional activity of CBP that
in turn regulates the CREB-mediated basal transcriptional
machinery of BDNF [29]. Since CREB signaling has been
reported to undergo modulation by various factors related to
different biological processes, there is a possibility that more
complex mechanism is involved in the scopolamine-mediated
alterations in BDNF message level. Our results also indicated that
the scopolamine has transient effects on neuroplasticity molecules.
French et al [30] also reported that the upregulation of the BDNF
message by cholinergic agonists disappeared after 24 h. Such
transient effects of scopolamine can be well correlated with its
short-term impairment of learning acquisition and memory.
We report for the first time that the scopolamine affects glial
plasticity marker GFAP in dose and time dependent manner.
AlthoughcholinergicregulationofGFAPhasnot been studied,some
studies regarding suppression of GFAP by antidepressants proposed
the involvement of transcription factors pCREB and NFkB
regulating the transcription of GFAP [31]. It has been reported
earlier that the muscarinic receptors lead to proliferation of astroglial
cells via activation of NFkB that elevated intracellular calcium level
and stimulated PKC signaling pathway [32]. Altogether, we suggest
Figure 7. Treatment with Ashwagandha i-Extract/withanone and protection against scopolamine-induced DNA damage and
oxidative stress. Level of expression of DNA damage marker (cH2AX) (A) and oxidative stress marker (reactive oxygen species, ROS) (B) in C6 cells
treated with either scopolamine or scopolamine and i-Extract/withaferin A/withanone as detected by immunocytochemistry with specific antibodies
and as described in material and methods are shown. Quantitation of cH2AX (C) and ROS (D) are shown, in which 200–300 cells were counted and
scored with high intensity of signal.
doi:10.1371/journal.pone.0027265.g007
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might be attributed to muscariniccontrol of transcription factors and
alteration in Ca
2+, PKC and MAP kinase pathway. Furthermore, it
can be speculated that the scopolamine mediated downregulation of
both the plasticity markers could be linked via a common M1
receptor mediated alteration in calcium homeostasis that in turn
modulates basal transcriptional machinery, particularly CREB
regulated transcription of BDNF and GFAP.
i-Extract attenuates scopolamine induced down-
regulation of BDNF and GFAP
We, for the first time, have investigated the neuroprotective
effect of i-Extract on scopolamine-mediated alterations and our
findings indicate that this extract markedly attenuates the effects of
the muscarinic antagonist. Such attenuation is more effective when
the extract is administered prior to scopolamine treatment. Similar
observations were made by Hung et al [33], when heat shock
pretreatment was given to prevent scopolamine-induced amnesia.
Besides attenuating muscarinic antagonism, the extract also up-
regulated BDNF message and protein levels. Similarly, the herbal
extract of wild ginseng also increases the expression of BDNF
mRNA in the rat hippocampus [34]. In case of BDNF, we have
analyzed transcript variant 1 and total protein level. We found that
the data on the message and the protein expression levels were not
corresponding completely. Such discrepancy between message and
protein level may be attributed to multilevel regulation of its
expression through different BDNF mRNA isoforms (I–IV) that
are all translated into a single protein [35]. Also, the mature
BDNF exhibits more remarkable change than its precursor form
that may be assigned to alterations in the activity of proteases [36]
that cleave the precursor form into mature form.
Similar to our observation, earlier studies have also demon-
strated the enhancement of GFAP protein level in response to i-
Extract treatment in C6 glioma cell line [37]. However, the mode
of neurochemical action of i-Extract was not clearly understood.
Based on differential effects of Ashwagandha root extract on
acetylcholinesterase activity and its enhanced M1 receptor binding
in basal forebrain nuclei [38,39], it can be suggested that
Ashwagandha exerts its neuroprotective action by agonizing
muscarinic receptors. One of the active constituents of Ashwa-
gandha extract, withanolide, has a steroidal structure [11].
Ashwagandha might stimulate signal cascades similar to steroids,
particularly estradiol that has also been shown to improve spatial
and working memory via cholinergic mechanisms [40,41]. Like
estradiol, i-Extract might activate three kinase pathways (CaMKII,
Akt and ERK/MAPK) that contribute to CREB phosphorylation
to different degrees. Widodo et al [42] have reported the anticancer
activities in i-Extract that may involve modulation of JAK- STAT
and MAP kinase signaling pathways. Taken together, we propose
that the i-Extract may attenuate scopolamine mediated alterations
of both BDNF and GFAP expressions by alteration of CREB
signaling, either directly by elevating intracellular calcium level, by
affecting Ca
2+/CAMK or via modulation of ERK/MAPK/CREB
signal transduction pathway that is known to be regulated by
muscarinic receptors [26].
From in vitro models of glial and neuronal cells, we found that
the scopolamine caused damage to cells that was considerably
recovered by pretreatment with i-Extract and its component
withanone. As seen in Figures 4 and 5, the damaged rounded cells
in response to scopolamine treatment were replaced with healthy
cells with extended neurites when treated with i-Extract and
withanone. On the other hand, neither the cell survival nor the
molecular markers of glial as well as neuronal cells showed any
recovery when cells were treated with withaferin A. As seen in
Figure 6, in neuroblastoma cells, increase in MAP-2 was observed
when scopolamine-treated cells were pretreated and recovered
either in i-Extract or withanone-supplemented medium. It
indicated neurite and axon growth that were also accompanied
by an increase in the expression of GAP-43 protein. The latter
plays a key role in the growth of axons and dendrites by
reorganization of the membrane cytoskeleton. GAP-43 has been
established as an important component for regenerative response
in the nervous system and is present at high level in neuronal
growth cones during development and axonal regeneration. Cells
treated with i-Extract and withanone indeed showed small
multipolar processes endorsing the increase in dendrites as shown
previously [43]. Similarly, analysis of NF-H expression showed its
increase when cells were pretreated and recovered either in i-
Extract or withanone supplemented medium. Immunostaining
revealed long processes indicating axonal growth (Figure 6). The
cells treated with withaferin A were unable to induce MAP2,
although a moderate increase in NF-H was observed. The data
suggested that withanone was most effective in restoration of
neuronal network. Decrease in PSD-95, an established post-
synaptic density marker in dendrites, in scopolamine treated cells
indicated impaired synaptic density and its recovery in i-Extract
and Withanone treated cells suggested recovery in the synaptic
functions. Of note, withaferin A also caused recovery in PSD-95
expression, although the changes in MAP2, NF-H and GAP43
were more pronounced with i-Extract and withanone. We also
found that the i-Extract and withanone protected the cells against
DNA and oxidative stress caused by scopolamine (Figure 7). These
data demonstrated that withanone is a predominant active
component that protected the cells against scopolamine-induced
damage. Further studies are warranted to reveal molecular details
and pathways involved in neuroprotective effects of i-Extract and
withanone that would promote their use for neuronal dysfunctions
associated with age and other pathologies.
Materials and Methods
Animals
Male Swiss albino strain mice of 12 weeks (25–30 g) inbred and
maintained in the animal house of Zoology Department, Banaras
Hindu University, Varanasi, India, were used similar to other
studies [44–46]. They were kept at 2462uC on a 12-h light/dark
cycle. Food and water were provided ad libitum. All the animal
experiments were approved by the institutional animal ethical
committee, Banaras Hindu University, Varanasi, India.
Cell culture
Glioma C6 (rat) and neuronal IMR32 (human) cell lines were
obtained from the Cell Resource Center for Biomedical Research,
Tohoku University, Japan. The cells were maintained in
Dulbecco’s Modified Eagle’s Medium DMEM (Invitrogen)
supplemented with 10% fetal bovine serum in a humidified
incubator (37uC and 5% CO2). Cells (40–50% confluency) were
pretreated with Ashwagandha leaf extract (i-Extract, 0.8 mg/ml),
withaferin A (0.2 mg/ml) and withanone (i-Factor, 5 mg/ml) for
24 h as described previously [43]. After 24 h, scopolamine (3 mM)
was added to the cells for 1 to 2 h. Culture medium was replaced
either with normal medium or medium supplemented with i-
Extract for another 24 h following which the cells were harvested
and processed for different assays.
Drug treatment
To determine the dose dependent effects of scopolamine
hydrobromide on memory function, increasing doses of scopol-
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0.9% normal saline (vehicle) was intraperitoneally administered to
mice. In many other studies, intraperitoneal injection of
scopolamine to rodents has been considered a reliable mode of
drug administration [47–49]. After 3 h of drug administration, the
cerebrum (cerebral cortex and underneath limbic structures) was
dissected out.
To determine the time dependent effect, mice were intraper-
itoneally injected with scopolamine (3 mg/kg BW) and cerebrum
was dissected after 1, 3, 6 and 24 h of treatment. Furthermore, to
assess the effect of i-Extract on scopolamine induced changes, mice
were divided into five groups. Group 1 mice were administered
with normal saline, Group 2 mice with normal saline followed by
scopolamine (3 mg/kg BW), and Group 3, 4 and 5 mice with
increasing doses of i-Extract (100 mg, 200 mg, 300 mg/kg BW)
orally followed by intraperitoneal injection of scopolamine (3 mg/
kg BW) after 2 h. All the five groups of mice were treated for 7
days and then cerebrum was removed after the last administration.
Furthermore, to assess the neuroprotective, therapeutic efficacy as
well as per se effect of i-Extract, its optimum dose of 200 mg/kg
BW was orally administered prior to, after and without
scopolamine treatments, respectively, for 7 days.
RNA isolation
Total RNA was isolated from the cerebrum of mice of different
experimental groups using TRI Reagent (Sigma, USA) following
the manufacturer’s instruction. It was estimated by taking
absorbance at 260 nm and RNA samples with A260/280$1.8
were used further. Total RNA from different groups was resolved
on 1.2% agarose formaldehyde gel and the integrity of RNA was
checked by ethidium bromide staining of 18S and 28S rRNA.
RT-PCR
RNA isolated from the cerebrum of mice of different
experimental groups was first reverse transcribed into cDNA
using reverse transcriptase. The resulting cDNA was used as
templates for subsequent PCR amplification using specific primers
for BDNF, GFAP and GAPDH as internal control [50,51]. Primer
sequence and PCR conditions are mentioned in Table 1. The
PCR products were resolved on 2% agarose gel. The signals were
scanned by AlphaImager system and analyzed by Alpha-EaseFC
software (Alpha Innotech Corp, USA). After extraction of total
RNA from mouse cerebrum, reverse transcription was performed.
Five microgram of RNA from each experimental group was
reverse transcribed and the resulting single-strand cDNA was
amplified by PCR, which was performed with specifically designed
primers for the genes in the study. For each gene (BDNF and
GFAP) specific primers were used and amplified separately using
optimal annealing temperature, number of cycles and annealing
conditions, as mentioned in Table 1. Parallel to this reaction, same
master mix of PCR reaction (cDNA, buffer, dNTP, H2O, Taq
Polymerase) was used with a pair of glyceraldehyde 3-phosphate
dehydrogenase (GAPDH)-specific primers to perform PCR of
GAPDH with its specific annealing temperature, number of cycles
and annealing conditions (mentioned in Table 1) as an internal
control for normalizing variations in RNA aliquots taken for RT
reactions and gel loading. PCR products were analyzed by
electrophoresis on 2% agarose gel and stained with ethidium
bromide. Band intensity was analyzed by densitometer.
Immunostaining
Cells were cultured and treated on glass coverslips placed in 12-
well culture dish. At the end of the treatment, coverslips were
washed with cold phosphate-buffered saline (PBS) and the cells
were fixed with pre-chilled methanol:acetone (1:1 v/v) mixture for
5–10 min. Fixed cells were washed with PBS, permeabilized with
0.2% Triton X-100 in PBS for 10 min, and blocked with 2%
bovine serum albumin (BSA) in PBS for 20 min. Cells were stained
with anti-GFAP (Sigma), anti-NF-H (Sigma), anti-MAP2 (Sigma),
anti-PSD-95 (Santa Cruz), anti-GAP 43 (Santa Cruz), cH2AX
(Millipore) antibodies. Immunostaining was visualized by second-
ary staining with Alexa-488 conjugated goat anti-rabbit antibody
(Molecular probes). After three to four washings with 0.2% Triton
X-100 in PBS (PBST), cells were overlaid with Fluoromount
(Difco) and examined under Carl Zeiss microscope using
epifluorescence optics. TUNEL staining was performed on cells
grown and treated onto coverslips using the ApopTagH Red In
Situ Apoptosis Detection kit (Millipore, Billerica, MA). ROS assay
was performed as described previously [52]
Western blotting
Mice were sacrificed by cervical dislocation and cerebrum was
removed, homogenized in lysis buffer (50 mM Tris HCl pH 7.4,
1 mM EDTA, 120 mM NaCl and protease inhibitor cocktail) and
centrifuged at 10006g for 10 min. The supernatant was subjected
to 15% SDS-PAGE, transferred to PVDF membrane, blocked in
5% skimmed milk/PBS, incubated overnight with primary
antibody (anti-BDNF polyclonal rabbit antiserum 1:1000, a gift
from Dr Masami Kojima, AIST, Japan; anti-GFAP polyclonal
rabbit antiserum 1:1000 and anti-b tubulin isotype III 1:5000
(Sigma), anti-GAPDH mouse monoclonal antiserum 1:5000
(Santa Cruz Biotech), washed twice in 0.1% PBST, incubated in
secondary antibody (goat-anti-rabbit IgG HRP 1:2000 for BDNF
and GFAP, and goat-anti-mouse IgG HRP 1:3000 for tubulin and
Table 1. Gene specific primer sequences and corresponding PCR conditions.
Gene name/
Amplicon length Primer Sequences Annealing conditions
Number of
cycles
Denature Anneal Extend
GAPDH/108 bp Forward 59 GTCTCCTGCGACTTCAG-39 94uC3 0s 5 2 uC3 0s 7 2 uC3 0s 2 6
Reverse 59-TCATTGTCATACCAGGAAATGAGC-39
GFAP/641 bp Forward 59-TTCCTGTACAGACTTCTCC-39 94uC6 0s 5 2 uC3 0s 7 2 uC4 5s 2 9
Reverse 59-CCCTTCAGGACTGCCTTAGT-39
BDNF/692 bp Forward 59-TGCCAGAGCCCCAGGTGTGA-39 94uC6 0s 6 3 uC3 0s 7 2 uC4 5s 3 2
Reverse 59-CTGCCCTGGGCCCATTCACG-39
doi:10.1371/journal.pone.0027265.t001
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to ECL detection. The band intensities were measured by spot
densitometry tool of AlphaEaseFC software (Alpha Innotech
Corp, USA). For western blotting, cells were grown and treated in
6-well plates. Protein samples (10–20 mg, estimated by Bradford
method) were harvested using Nonidet-P40 lysis buffer (20 mM
Tris, 100 mM EDTA, 100 mM EGTA, 100 mM PMSF, 150 mM
NaCl, and 1% NP-40), separated in SDS-polyacrylamide gels, and
electroblotted onto PVDF membranes (Millipore) using a semidry
transfer blotter (Biometra, Tokyo, Japan). Immunoblotting was
performed with antibodies against GFAP (Sigma), actin (Chemi-
con International, Temecula, CA), NF-H (Sigma) and MAP-2
(Sigma). The immunoblots were incubated with horseradish
peroxidase (HRP)-conjugated goat anti-mouse or anti-rabbit
antibodies (Santa Cruz Biotech) and detected using ECL substrate
(Amersham Pharmacia Biotech/GE Healthcare, Piscataway, NJ).
Densitometric quantitation of the representative immunoblots was
carried out using the ImageJ software (National Institute of
Health).
Statistical analysis
Each experiment was repeated three times (n=9/group). For
RT-PCR, the signal intensity of BDNF and GFAP message was
analyzed after normalization against the signal intensity of internal
control, GAPDH. The data are presented as a histogram with the
mean (6SEM) of three values calculated as percentage relative
density values (RDV) of BDNF/GAPDH and GFAP/GAPDH.
For western blotting, the signal intensity of BDNF and GFAP was
analyzed after normalization against the signal intensity of b-
tubulin or GAPDH. The data are presented as a histogram with
the mean (6SEM) of three values calculated as RDV of BDNF/b-
tubulin, BDNF/GAPDH, GFAP/b-tubulin and GFAP/GAPDH.
Statistical analysis was performed by one way analysis of variance
(ANOVA) followed by post hoc tests of Student-Newman-Keuls
method using SigmaPlot, version 2.0, Jandel Scientific Software.
The data were reported as mean (6 SEM) and P values,0.05
were considered as significant.
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